跳到正文
原文
Endpoints News 生物医药· ENDPOINTS·· 15 天前AI 评分26

Rezera 销售增长推动 RevMed 股价上涨

Rasonque sales drive RevMed's stock; whistleblower sues Madrigal over MASH

AI 导读

Rezera 是一款 RAS 药物,RevMed 公司报告其早期销售取得增长,导致公司股价上涨。

正文

Plus news about Rez­era, ANI Phar­ma­ceu­ti­cals, Cloud­break Phar­ma and Ana­heim Bio.

RevMed’s stock jumps on ear­ly Ra­sonque sales: The RAS drug de­vel­op­er re­port­ed sales of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news